Identification of a Gain-of-Function LIPC Variant as a Novel Cause of Familial Combined Hypocholesterolemia

Background: Atherosclerotic cardiovascular disease is the main cause of mortality worldwide and is strongly influenced by circulating low-density lipoprotein (LDL) cholesterol levels. Only a few genes causally related to plasma LDL cholesterol levels have been identified so far, and only 1 gene, ANGPTL3, has been causally related to combined hypocholesterolemia. Here, our aim was to elucidate the genetic origin of an unexplained combined hypocholesterolemia inherited in 4 generations of a French family. Methods: Using next-generation sequencing, we identified a novel dominant rare variant in the LIPC gene, encoding for hepatic lipase, which cosegregates with the phenotype. We characterized the impact of this LIPC-E97G variant on circulating lipid and lipoprotein levels in family members using nuclear magnetic resonance–based lipoprotein profiling and lipidomics. To uncover the mechanisms underlying the combined hypocholesterolemia, we used protein homology modeling, measured triglyceride lipase and phospholipase activities in cell culture, and studied the phenotype of APOE*3.Leiden.CETP mice after LIPC-E97G overexpression. Results: Family members carrying the LIPC-E97G variant had very low circulating levels of LDL cholesterol and high-density lipoprotein cholesterol, LDL particle numbers, and phospholipids. The lysophospholipids/phospholipids ratio was increased in plasma of LIPC-E97G carriers, suggestive of an increased lipolytic activity on phospholipids. In vitro and in vivo studies confirmed that the LIPC-E97G variant specifically increases the phospholipase activity of hepatic lipase through modification of an evolutionarily conserved motif that determines substrate access to the hepatic lipase catalytic site. Mice overexpressing human LIPC-E97G recapitulated the combined hypocholesterolemic phenotype of the family and demonstrated that the increased phospholipase activity promotes catabolism of triglyceride-rich lipoproteins by different extrahepatic tissues but not the liver. Conclusions: We identified and characterized a novel rare variant in the LIPC gene in a family who presents with dominant familial combined hypocholesterolemia. This gain-of-function variant makes LIPC the second identified gene, after ANGPTL3, causally involved in familial combined hypocholesterolemia. Our mechanistic data highlight the critical role of hepatic lipase phospholipase activity in LDL cholesterol homeostasis and suggest a new LDL clearance mechanism.

[1]  Steven J Novick,et al.  Blocking endothelial lipase with monoclonal antibody MEDI5884 durably increases high density lipoprotein in nonhuman primates and in a phase 1 trial , 2021, Science Translational Medicine.

[2]  A. Marais,et al.  Atherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants. , 2020, Journal of clinical lipidology.

[3]  Thomas M. Keane,et al.  Twelve years of SAMtools and BCFtools , 2020, GigaScience.

[4]  Oliver T. Bruns,et al.  Lysosomal lipoprotein processing in endothelial cells stimulates adipose tissue thermogenic adaptation. , 2020, Cell metabolism.

[5]  J. Pais de Barros,et al.  Deletion of lysophosphatidylcholine acyltransferase 3 in myeloid cells worsens hepatic steatosis after a high-fat diet , 2020, Journal of lipid research.

[6]  M. Hussain,et al.  New Classification and Management of Abetalipoproteinemia and Related Disorders. , 2020, Gastroenterology.

[7]  R. Redon,et al.  Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[8]  D. Rader,et al.  LDL-Cholesterol Reduction by ANGPTL3 Inhibition in Mice Is Dependent on Endothelial Lipase. , 2020, Circulation research.

[9]  J. Pais de Barros,et al.  Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients , 2020, Alimentary pharmacology & therapeutics.

[10]  Robin van Eenige,et al.  RandoMice, a novel, user-friendly randomization tool in animal research , 2020, PloS one.

[11]  Jonathan C. Cohen,et al.  Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance , 2020, Journal of Lipid Research.

[12]  P. Moulin,et al.  Development of a new expanded next‐generation sequencing panel for genetic diseases involved in dyslipidemia , 2020, Clinical genetics.

[13]  Ryan L. Collins,et al.  Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes , 2020, Nature Communications.

[14]  Jun Zhu,et al.  Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study , 2020, The Lancet.

[15]  R. Krauss,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel , 2020, European heart journal.

[16]  H. M. Draisma,et al.  Heritability estimates for 361 blood metabolites across 40 genome-wide association studies , 2020, Nature Communications.

[17]  F. Raal,et al.  Lomitapide and Mipomersen—Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis , 2019, Current Atherosclerosis Reports.

[18]  D. Ledbetter,et al.  Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders , 2019, Nature Communications.

[19]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2019 .

[20]  Thomas M. Smith,et al.  Structure of lipoprotein lipase in complex with GPIHBP1 , 2019, Proceedings of the National Academy of Sciences.

[21]  E. Fisher,et al.  SR-B1 Drives Endothelial Cell LDL Transcytosis via DOCK4 to Promote Atherosclerosis , 2019, Nature.

[22]  A. Veena,et al.  Files , 2018, Introduction to Python Programming.

[23]  M. Hof,et al.  Pediatric lipid reference values in the general population: The Dutch lifelines cohort study. , 2018, Journal of clinical lipidology.

[24]  J. Flowers,et al.  Origins and geographic diversification of African rice (Oryza glaberrima) , 2018, bioRxiv.

[25]  R. Hegele,et al.  The complex molecular genetics of familial hypercholesterolaemia , 2018, Nature Reviews Cardiology.

[26]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[27]  Maximilian Haeussler,et al.  CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens , 2018, Nucleic Acids Res..

[28]  Pierre Lindenbaum,et al.  Bioalcidae, Samjs and Vcffilterjs: Object-oriented Formatters and Filters for Bioinformatics Files , 2018, Bioinform..

[29]  R. Sinke,et al.  Genetics, Lifestyle, and Low-Density Lipoprotein Cholesterol in Young and Apparently Healthy Women , 2018, Circulation.

[30]  L. Wood,et al.  LipSpin: A New Bioinformatics Tool for Quantitative 1H NMR Lipid Profiling. , 2018, Analytical chemistry.

[31]  M. Linton,et al.  SR-BI: A Multifunctional Receptor in Cholesterol Homeostasis and Atherosclerosis , 2017, Trends in Endocrinology & Metabolism.

[32]  M. Ståhlman,et al.  The BUME method: a new rapid and simple chloroform-free method for total lipid extraction of animal tissue , 2016, Scientific Reports.

[33]  J. Pais de Barros,et al.  Short Term Palmitate Supply Impairs Intestinal Insulin Signaling via Ceramide Production* , 2016, The Journal of Biological Chemistry.

[34]  Richard H. Henchman,et al.  Water Determines the Structure and Dynamics of Proteins. , 2016, Chemical reviews.

[35]  B. Nordestgaard Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[36]  P. Subbaiah,et al.  Regulation of hepatic lipase activity by sphingomyelin in plasma lipoproteins. , 2015, Biochimica et biophysica acta.

[37]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[38]  J. Ribalta,et al.  Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy[S] , 2014, Journal of Lipid Research.

[39]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[40]  A. Rudnitskaya,et al.  A comparison of five lipid extraction solvent systems for lipidomic studies of human LDL[S] , 2013, Journal of Lipid Research.

[41]  Sonia Shah,et al.  Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study , 2013, The Lancet.

[42]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[43]  J. VandeBerg,et al.  Vertebrate hepatic lipase genes and proteins: a review supported by bioinformatic studies. , 2011, Open access bioinformatics.

[44]  Weijun Jin,et al.  Determination of lipoprotein lipase activity using a novel fluorescent lipase assay[S] , 2011, Journal of Lipid Research.

[45]  Oliver T. Bruns,et al.  Brown adipose tissue activity controls triglyceride clearance , 2011, Nature Medicine.

[46]  Marco Biasini,et al.  Toward the estimation of the absolute quality of individual protein structure models , 2010, Bioinform..

[47]  Jonathan C. Cohen,et al.  Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. , 2010, The New England journal of medicine.

[48]  B. Nordestgaard,et al.  Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. , 2009, The Journal of clinical endocrinology and metabolism.

[49]  J. Jukema,et al.  Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[50]  Z. Nong,et al.  Hepatic lipase, lipoprotein metabolism, and atherogenesis. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[51]  D. Rader,et al.  Dose-Dependent Acceleration of High-Density Lipoprotein Catabolism by Endothelial Lipase , 2003, Circulation.

[52]  Ron D. Appel,et al.  ExPASy: the proteomics server for in-depth protein knowledge and analysis , 2003, Nucleic Acids Res..

[53]  Sungshin Y. Choi,et al.  Endothelial lipase Published, JLR Papers in Press, September 1, 2002. DOI 10.1194/jlr.R200011-JLR200 , 2002, Journal of Lipid Research.

[54]  E. Sijbrands,et al.  Hepatic lipase: a pro- or anti-atherogenic protein? , 2002, Journal of lipid research.

[55]  D. Rader,et al.  Characterization of the lipolytic activity of endothelial lipase. , 2002, Journal of lipid research.

[56]  R. F. Hoyt,et al.  In vivo evidence for both lipolytic and nonlipolytic function of hepatic lipase in the metabolism of HDL. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[57]  P. Connelly,et al.  The role of hepatic lipase in lipoprotein metabolism. , 1999, Clinica chimica acta; international journal of clinical chemistry.

[58]  S. Crawford,et al.  Plasma clearance and liver uptake of chylomicron remnants generated by hepatic lipase lipolysis: evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway. , 1999, Journal of lipid research.

[59]  J. Tait,et al.  Phosphatidylserine Receptors: Role of CD36 in Binding of Anionic Phospholipid Vesicles to Monocytic Cells* , 1999, The Journal of Biological Chemistry.

[60]  R. F. Hoyt,et al.  Hepatic lipase facilitates the selective uptake of cholesteryl esters from remnant lipoproteins in apoE-deficient mice. , 1998, Journal of lipid research.

[61]  R. Mahley,et al.  Overexpression of Hepatic Lipase in Transgenic Mice Decreases Apolipoprotein B-containing and High Density Lipoproteins , 1998, The Journal of Biological Chemistry.

[62]  M. Müller,et al.  Immortalized human hepatocytes as a tool for the study of hepatocytic (de-)differentiation , 1997, Cell Biology and Toxicology.

[63]  N. Maeda,et al.  Hepatic Lipase Deficiency Increases Plasma Cholesterol but Reduces Susceptibility to Atherosclerosis in Apolipoprotein E-deficient Mice* , 1997, The Journal of Biological Chemistry.

[64]  K. Dugi,et al.  Human Hepatic and Lipoprotein Lipase: The Loop Covering the Catalytic Site Mediates Lipase Substrate Specificity (*) , 1995, The Journal of Biological Chemistry.

[65]  J. K. Kruijt,et al.  Selective liver targeting of antivirals by recombinant chylomicrons — a new therapeutic approach to hepatitis B , 1995, Nature Medicine.

[66]  D. Brasaemle,et al.  Hepatic lipase treatment of chylomicron remnants increases exposure of apolipoprotein E. , 1993, Journal of lipid research.

[67]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[68]  A. Nilsson,et al.  A role for hepatic lipase in chylomicron and high density lipoprotein phospholipid metabolism. , 1984, Journal of lipid research.

[69]  I. Nolte,et al.  Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants , 2017 .

[70]  Claude-Alain H. Roten,et al.  Theoretical and practical advances in genome halving , 2004 .

[71]  H. Brewer,et al.  Hepatic lipase promotes the selective uptake of high density lipoprotein-cholesteryl esters via the scavenger receptor B 1 , 1999 .

[72]  H. Berman,et al.  The Protein Data Bank. , 2002, Acta crystallographica. Section D, Biological crystallography.